pmed.1003998.s001.tif (2.94 MB)
SLEFS in all patients.
figure
posted on 2022-06-07, 17:32 authored by Chris C. Parker, Nicholas D. James, Christopher D. Brawley, Noel W. Clarke, Adnan Ali, Claire L. Amos, Gerhardt Attard, Simon Chowdhury, Adrian Cook, William Cross, David P. Dearnaley, Hassan Douis, Duncan C. Gilbert, Clare Gilson, Silke Gillessen, Alex Hoyle, Rob J. Jones, Ruth E. Langley, Zafar I. Malik, Malcolm D. Mason, David Matheson, Robin Millman, Mary Rauchenberger, Hannah Rush, J Martin Russell, Hannah Sweeney, Amit Bahl, Alison Birtle, Lisa Capaldi, Omar Din, Daniel Ford, Joanna Gale, Ann Henry, Peter Hoskin, Mohammed Kagzi, Anna Lydon, Joe M. O’Sullivan, Sangeeta A. Paisey, Omi Parikh, Delia Pudney, Vijay Ramani, Peter Robson, Narayanan Nair Srihari, Jacob Tanguay, Mahesh K. B. Parmar, Matthew R. SydesAdjusted HR = 1.00 (95% CI 0.90 to 1.13; p = 0.931). HR, hazard ratio; RT, radiotherapy to the prostate; SLE, symptomatic local event; SOC, standard of care.
(TIF)
History
Usage metrics
Keywords
xlink "> stampedeworld health organizationsymptomatic local eventsstratification factors agesecondary outcome measuresprimary outcome measurefpms ), adjustedflexible parametric modelsfirst 2 years30 summary scoreterm urinary toxicityterm bowel toxicity0 · 640 · 164xlink "> patientssoc versus 156secondary care sitesrt toxicity eventsplanned docetaxel usemetastatic burden classifiablemetastatic prostate cancer1 stratified allocationlow metastatic burdenmetastatic burdentreatment allocationterm resultsterm findingsci 0low burdenburden diseasewithout detrimentunited kingdomseptember 2016regular aspirinperformance statusnonsteroidal antinodal involvementnewly diagnosedjanuary 2013inflammatory drughazard ratiograde 3final analysis3 months202 deaths10 soc
Licence
Exports
RefWorks
BibTeX
Ref. manager
Endnote
DataCite
NLM
DC